Pioneering next-gen thermal solutions, the Company is offering an exclusive EAP to revolutionize AI and HPC cooling through photonic innovation To empower businesses with next-gen thermal solutions in ...

ANN ARBOR, Mich., Nov. 19, 2024 /PRNewswire/ -- Ambient Biosciences, a pioneering life science company, today announced the launch of its Early Access Program (EAP), seeking partners to trial ...

Ambient Biosciences, a pioneering life science company, today announced the launch of its Early Access Program (EAP), seeking ...

Northwestern State University's Department of Biology and Microbiology has made an agreement with the University of Texas at Tyler.

Lung cancer diagnostics developer LungLife AI reported significant progress in the commercialisation of its ‘LungLB’ test on ...

The 2024 election has brought significant changes, with Donald Trump returning to the White House after securing both the ...

TIMMINS - Ontario’s new mental health initiative will provide essential support to first responders in Timmins and the ...

In an emailed statement, Eisai told Fierce Pharma that it has made the “incredibly difficult decision to discontinue our PHNX Phase 3 study … and the Extended Access Program … exploring the ...

MIPLYFFA, the first FDA-approved treatment for Niemann-Pick disease type C, is available at Zevra’s specialty pharmacy for ...

The Board and Chief Executive Officer of Cereno Scientific AB here present the interim report for Q3 2024 (July 1-September 30). Summary of the interim report for Q3 2024 (July 1-September 30) Cereno ...

France led the way with early access programmes, introducing its Temporary Authorization Program in 1992 and introducing a major reform in 2021 to simplify the schemes and accelerate patient access.